Professor Timothy J Perren

Medical oncology


  • Fee assured

Specialises in

  • Breast
  • Gynaecology

About me

Consultant Medical Oncologist who specialises in providing high quality cancer diagnosis, medical treatment, and follow-up for women (and men) with breast cancer. I have a long professional clinical and research career in diagnosis and treatment for patients with gynaecological cancer, however I am no longer taking referrals for ovarian, uterine or cervical cancer.

Professor Perren is a senior consultant oncologist at Spire Leeds Hospital and St James’s Institute of Oncology in Leeds. Professor Perren specialises in the medical treatment of cancers using chemotherapy, hormonal therapy, supportive therapies such as bisphosphonates, and the new targeted molecular therapies such as trastuzumab (Herceptin) pertuzumab (Perjeta), trastuzumab emtansine (Kadcyla), lapatinib (Tyverb), everolimus (Afinitor), bevacizumab (Avastin), as well as the new CDK 4/6 inhibitor drugs such as palbociclib, ribociclib and abemaciclib.

Modern treatment for cancer requires the careful integration of diagnostic procedures, surgical treatment, medical therapies with chemotherapy, targeted molecular therapies, endocrine therapy, and radiotherapy. This is brought about through a multidisciplinary team approach where pathologists, radiologists, oncologists, surgeons, and specialist nurses meet on a regular basis to consider the diagnosis and optimal treatment for individual patients.

Professor Perren is a member of the multidisciplinary team for breast cancer at the Leeds Cancer Centre which is based at the St James’s Institute of Oncology within the Leeds Teaching Hospitals NHS Trust. Professor Perren works with the same team of surgeons, radiologists, and pathologists in the private sector as he does in the NHS.

Modern cancer treatment is increasingly becoming tailored to the individual patient and their particular cancer through careful analysis of the nature and extent of the disease together with information regarding certain biological and molecular features exhibited by the cancer. So one patient with, say breast cancer, will not necessarily need to have the same treatment as another patient who apparently has the same disease. Professor Perren uses molecular analysis of the individual tumour of patients where appropriate to guide treatment using technologies such as Oncotype DX or Molecular Profiling from organisations such as Caris, Myriad and OncoDNA.

Oncologists are involved at all stages in the pathway of care, and today, where appropriate, chemotherapy or hormonal therapy maybe used as the initial form of treatment, sometimes referred to as neo-adjuvant therapy.

Professor Perren has many years of expertise in chemotherapy and hormonal therapy for breast cancer (in men as well as in women) and the whole range of gynaecological cancers. The gynaecological cancers include, ovarian cancer; primary peritoneal cancer – a condition which is often confused with ovarian cancer; ovarian germ cell tumours (often known as ovarian teratomas or yolk sac tumours); fallopian tube cancer; endometrial cancer (cancer of the lining of the womb); cervix or cervical cancer, vaginal cancer; vulval cancer. There are a number of rarer gynaecological malignancies such as carcinosarcomas (sometimes known as mixed mullerian tumour), or various other forms of sarcoma which can affect either the ovary or the endometrium. Professor Perren is however no longer taking referrals for gynaecological cancers.

Professor Perren has expertise in treating patients with both newly diagnosed early cancer, and cancer which has recurred after previous treatments. On occasions patients are diagnosed with advanced cancer and it is not clear which organ the cancer has developed from; this is known as cancer of unknown primary site. Professor Perren, with his colleagues in diagnostic radiology and pathology, are very familiar with the appropriate investigation of this form of cancer so that optimal treatments may be offered.

Areas of interest

Breast cancer; Chemotherapy; endocrine therapy; hormonal therapy; trastuzumab; Herceptin; pertuzumab; Perjeta; trastuzumab emtansine; Kadcyla; CDK 4/6 inhibitors; palbociclib; ribociclib; abemaciclib; immunotherapy in the context of clinical trials; bisphosphonate therapy; zoledronic acid; ibandronic acid; targeted molecular therapy; clinical trials; molecular profiling

Medical secretaries


  • Video and telephone consultations
About me
My qualifications & training
My private practice
Consultant's practices
Information for healthcare professionals

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

  • X0001

    Clinical supervision and planning for the delivery of chemotherapy regimens for 0 to 7 days - (>50)

    Spire Leeds Hospital (>50)

  • X0003

    Clinical supervision and planning for delivery of chemotherapy cycle 1 - 21 days - (>50)

    Spire Leeds Hospital (>50)

  • X0004

    Clinical supervision and planning for delivery of chemotherapy cycle 1 - 28 days - (>50)

    Spire Leeds Hospital (>50)

  • AA843

    Clinical supervision and planning for delivery of chemotherapy cycle in the member's home 1-21 days - (5-50)

  • X0002

    Clinical supervision and planning for delivery of chemotherapy cycle 1 - 14 days - (5-50)

    Spire Leeds Hospital (5-50)

  • AA841

    Clinical supervision and planning for delivery of chemotherapy cycle in the member's home 0-7 days - (5-50)

  • Show All (7)...
Report this page Edit details Print page

The information contained on Finder is submitted by consultants, therapists and healthcare services, and these third parties declare it to be correct and compliant with their relevant regulatory bodies' standards and codes of conduct. We're unable to guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use here.